

ASH Annual Meeting, December 7-10, 2024

Presentation schedule for Winship Cancer Institute of Emory University faculty, APPs and trainees

All times listed in Pacific Time



Friday, December 6, 2024

Time	Location	Type	Session	Presenter	Title
11:00 AM-2:00 PM	Room 6A (San Diego Convention Center)	Friday Satellite Symposia	From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice	Ajay K. Nooka, MD, MPH (speaker)	
1:30 PM-2:00 PM	Station 5 (Gaslamp Quarter)	ASH-a-Palooza Program	Blood Drop: PhD	Benjamin G. Barwick, PhD (speaker)	
1:30 PM-3:50 PM	Cafe Sevilla Restaurant (Gaslamp Quarter)	ASH-a-Palooza Program	Blood Buddies: PhD/Lab	Lawrence H. Boise, PhD (panelist)	
1:30 PM-3:50 PM	Cafe Sevilla Restaurant (Gaslamp Quarter)	ASH-a-Palooza Program	Blood Buddies: Adult Clinical Classical Hematology	Christine L. Kempton, MD (panelist)	
2:10 PM-3:25 PM	Room 3 (San Diego Convention Center)	Scientific Workshop	Challenges in Red Blood Cell Quality Testing	Vivien Sheehan, MD, PhD (speaker)	The Need for Red Cell Function Testing: From Clinical Trials to Patient Care
3:00 PM-6:00 PM	Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)	Friday Satellite Symposia	Addressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know	Sagar Lonial, MD (chair)	
3:00 PM-6:00 PM	Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)	Friday Satellite Symposia	Complex Cases in the Community Clinic: Managing Diverse Hematologic Malignancies	Nisha S. Joseph, MD (speaker)	

Saturday, December 7, 2024

Time	Location	Type	Session	Presenter	Title
8:00 AM-9:00 AM	Aqua 310 (Hilton San Diego Bayfront)	How I Treat Program	How I Treat	Christine L. Kempton, MD	How I Treat: Options for Long-Term Management of Hemophilia (ticketed session for in-person participants)
9:30 AM-10:45 AM	Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)	Education Program	A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma	Xu Ji, PhD	The Lasting Impact of the ACA: How Medicaid Expansion Reduces Outcome Disparities in AYAs With Leukemia and Lymphoma
12:00 PM-1:30 PM	Room 11 (San Diego Convention Center)	Oral	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease	Andres Chang, MD, PhD (moderator)	
12:45 PM	Room 29 (San Diego Convention Center)	Oral	322. Hemophilia A and B: Clinical and Epidemiological: Beyond Efficacy of Hemostatic Agents in Hemophilia: Exploring Pharmacokinetics, Dosing Regimens, and Special Populations	Shalini Vemuru, MD	Comparing the Risk of Thrombotic Events in Older Persons with Hemophilia a on Emicizumab Prophylaxis to Non-Emicizumab Products: A Single Center Observational Cohort Study
2:00 PM-3:30 PM	San Diego Ballroom AB (Marriott Marquis San Diego Marina)	Oral	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes	Benjamin Barwick, PhD	DNA Methylation Analysis of CoMMpass Reveals Distinct Epigenetic Programs of High-Risk Disease
2:30 PM	Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)	Oral	653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies	Craig C. Hofmeister, MD	A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma
4:00 PM-5:35 PM	Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)	Scientific Program	Joint Session: Molecular Characterization of Lymphomas in Children, Adolescents, and Young Adults	Jean L. Koff, MD, MSc (co-chair)	
4:30 PM	Room 30 (San Diego Convention Center)	Oral	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Tools and Biomarkers for Improving Sickle Cell Disease Treatments	Soumitri Sil, PhD	Integrative Strong Body and Mind Training for Sickle Cell Disease (I-STRONG)—an Interdisciplinary, Multicomponent Treatment Approach for Pediatric Chronic SCD Pain
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	626. Aggressive Lymphomas: Clinical and Epidemiological: Poster I	Katelin Baird	Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis

5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I	Akshay Patwardhan	Proposed Use of the Microfluidic Impedance Red Cell Assay (MIRCA) to Identify Individuals with Sickle Cell Disease in Need of Second Line Therapies
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I	Tarun Jain	Acuity of Illness at Initial Presentation Mediates Early Mortality in Adolescent and Young Adult Leukemia
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I	Erin Frost	The Impact of Structural Inequity and Adverse Social Determinants of Health on Hematopoietic Cell Transplant Access in Pediatric Patients with Hematologic Malignancies and Myelodysplastic Syndromes
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	628. Aggressive Lymphomas: Cellular Therapies: Poster I	Pranav Santapuram	Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I	Kennedy Goldsborough, PhD	IHP-102 Reduces Hypoxia-Induced Pain Behaviors in Townes SCD Mice
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	322. Hemophilia A and B: Clinical and Epidemiological: Poster I	Prashant Raghavendran, DO	Immune Toleration Induction with Emicizumab in Hemophilia a Patients with Inhibitors: A Systematic Review
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I	Theodora Alese	"Endothelialized" Hemostasis-on-a-Chip Reveals Rapid Platelet Recruitment By Locally Concentrated Ultra-Large Von Willebrand Factor (VWF) Release from Endothelial Cells Surpasses Plasma and Platelet VWF in Initiating Hemostasis
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I	Abraham Attah, MD	Maternal and Fetal Outcomes in Sickle Cell Disease: Single Center Review
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I	Dunia Hatabah, MD	Exploring N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE)
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	603. Lymphoid Oncogenesis: Basic: Poster I	Marina E. Michaud	Single-Cell Profiling of the Immune Response Following Siglec 15 Knockout in Leukemia Cells
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	603. Lymphoid Oncogenesis: Basic: Poster I	Robert M. Chavez	Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	654. Multiple Myeloma: Pharmacologic Therapies: Poster I	Nisha S. Joseph, MD	Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I	Rawan Korman, MD	Secretary Phospholipase A2(sPLA2) in Patients with Sickle Cell Disease (SCD) Hospitalized for Vaso-Occlusive Pain Episodes (VOE)
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	654. Multiple Myeloma: Pharmacologic Therapies: Poster I	Ajay K. Nooka, MD, MPH	Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	101. Red Cells and Erythropoiesis, Excluding Iron: Poster I	Moira M. Lancelot, MD	BMI-1 Transduced Human Erythroid Cells: A Representative System for Modeling Transcriptional Programs during Terminal Erythroid Differentiation
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I	Pamela B. Allen, MD	Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	904. Outcomes Research: Hemoglobinopathies: Poster I	Rhonda Smith-Wright, PhD	Intersection of Pain-Related Healthcare Utilization with Neighborhood Factors in Adults Living with Sickle Cell Disease
6:00 PM-9:00 PM	Marina Ballroom E (Marriott Marquis San Diego Marina)	Special-Interest Session	Hematology Inclusion Pathway (HIP) Oral Presentations - Classical Hematology	Dailia B. Francis, MD, PhD (moderator)	
6:00 PM-9:00 PM	Marina Ballroom F (Marriott Marquis San Diego Marina)	Special-Interest Session	Hematology Inclusion Pathway (HIP) Oral Presentations - Health Services Outcomes	Staci D. Arnold, MD, MBA, MPH (moderator)	
6:00 PM-9:00 PM	Marina Ballroom D (Marriott Marquis San Diego Marina)	Special-Interest Session	Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology	Kristopher Adrian Knight	Development of a Novel L-Asparaginase with Enhanced Properties Using Ancestral Sequence Reconstruction
6:00 PM-9:00 PM	Marina Ballroom E (Marriott Marquis San Diego Marina)	Special-Interest Session	Hematology Inclusion Pathway (HIP) Oral Presentations - Classical Hematology	Sarah Mansour	Methionine Sulfoxide and Other Metabolites from Bronchoalveolar Lavage Are Associated with Neutrophil-Dominated Lung Disease in Early Cystic Fibrosis

Sunday, December 8, 2024

Time	Location	Type	Session	Presenter	Title
9:30 AM-11:00 AM	Room 25 (San Diego Convention Center)	Oral	321. Coagulation and Fibrinolysis: Basic and Translational. A Coagulation Grab Bag	Karen Zimowski	F5-Atlanta induced Exon Splicing

11:15 AM-12:15 PM	Halls G-H - Blood Journals Studio (San Diego Convention Center)	ASH Poster Walks	ASH Poster Walk on What's New in Complement-Related Diseases? Hosted by Blood Red Cells & Iron (for in-person participants)	Michelle L. Schoettler, MD	Terminal Complement Activation in Children with Sinusoidal Obstructive Syndrome after Hematopoietic Cell Transplantation
12:00 PM-1:30 PM	Ballroom 20CD (San Diego Convention Center)	Oral	Hodgkin Lymphomas: Clinical and Epidemiological: Optimization of Therapy	Sharon M. Castellino, MD, MSc (moderator)	
4:30 PM-6:00 PM	Room 24 (San Diego Convention Center)	Special-Interest Session	Symposium for Mid-Career Hematologists	Robert F. Sidonio, Jr., MD, MSc	Your Next Job - How to Identify Academic Opportunities with the Best Payback
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II	Michelle L. Schoettler, MD	Terminal Complement Activation in Children with Sinusoidal Obstructive Syndrome after Hematopoietic Cell Transplantation
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II	Justin Yoo	Long-Term Therapy with GBT021601 and Moderate Chronic Transfusion Therapy Prevent the Development of Hyperalgesia
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II	Marina Michaud	Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II	Andres Chang, MD, PhD	PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	907. Outcomes Research: Plasma Cell Disorders: Poster II	Lilly Gu, MD	Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II	Xu Ji, PhD	Residential Economic and Racial Segregation Is Associated with Acuity and Severity of Pediatric Leukemia at Presentation
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II	Joseph Rimando, MD	Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis

6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II	Christopher Chambliss, PhD	Placental Abnormalities in the Humanized Mouse Model of Sickle Cell Disease
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	653. Multiple Myeloma: Clinical and Epidemiological: Poster II	Lorenzo Cani, MD	Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II	Giorgi Maziashvili, MD	Procalcitonin Elevation in Children with Sickle Cell Disease (SCD) Requiring Hospitalization for Acute Vaso-Occlusive Pain (VOE)
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II	Carlos Alberto Lopez, MD, MPH	Treatment-Related Neuropathy Following Brentuximab-Vedotin in African Americans Treated for Lymphoma: A Retrospective Chart Review
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	802. Chemical Biology and Experimental Therapeutics: Poster II	Fernanda Marconi Roversi, PhD	PIM447, a Pan-PIM Kinase Inhibitor, in Combination with Venetoclax Exerts a Potent Anti-Tumor Activity in the Bone Marrow Niche
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II	Robert F. Sidonio, Jr., MD, MSc	Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD

Monday, December 9, 2024

Time	Location	Type	Session	Presenter	Title
10:30 AM-11:45 AM	Room 28 A-D (San Diego Convention Center)	Education Program	Anticoagulation SOS: Navigating Monitoring Conundrums	Cheryl L. Maier, MD, PhD	Troubleshooting Heparin Resistance
10:30 AM-12:00 PM	Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)	Oral	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in Myeloma	Benjamin G. Barwick, PhD (moderator)	
10:30 AM-12:00 PM	Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)	Oral	654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma	Nisha S. Joseph, MD (moderator)	

10:30 AM-12:00 PM	San Diego Ballroom AB (Marriott Marquis San Diego Marina)	Oral	902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow - Improving Access to Blood Cancer Treatments and Trials	Xu Ji, PhD (moderator)	
12:00 PM-1:15 PM	Marina Ballroom D (Marriott Marquis San Diego Marina)	Special-Interest Session	DEI Community Networking Lunch (for in-person participants)	Sarwish Rafiq, PhD (moderator)	
2:45 PM-4:00 PM	Room 24 (San Diego Convention Center)	Spotlight Session	Gene Therapy and Hemophilia A: What Is the Future of Curative Therapy in the Age of Emicizumab?	Christine L. Kempton, MD, MSc	Unknowns of Gene Therapy and Successes of Medical Therapies for Hemophilia A
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III	Jason Payne	A Large Cluster of Parvovirus B19 Aplastic Crisis in Children with Sickle Cell Disease in Atlanta, GA (Dec 2023- July 2024)
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III	Michelle L. Schoettler, MD	A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III	Shannon Matulis	Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III	Hope Mumme	CAR-Machine: CAR-T Cell Target Identification Platform for Pediatric Acute Leukemia and Implementation to Identify Novel Targets for Pediatric AML
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	801. Gene Therapies: Poster III	Britney Hernandez	Rheological Comparison of Red Cells from Individuals with SCD Treated with Gene Therapy, Haploidentical Transplantation or Hydroxyurea
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	802. Chemical Biology and Experimental Therapeutics: Poster III	Justin Adeyeye	Development of Humanized Antibodies Against Vasoactive Intestinal Polypeptide for Increased T Cell Anti-Leukemia Activity
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III	Kristopher Knight	Ancestral L-Asparaginases Are Cytotoxic Against ALL Cell Lines with Predicted Reduced Immunogenicity
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III	Rowan Brothers	OEF Measured with Diffuse Optical Spectroscopies As a Biomarker of Silent Stroke in Pediatric Sickle Cell Anemia

6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	506. Bone Marrow Microenvironment: Poster III	Alejandro De Janon	High Throughput and Long-Term Human Bone Marrow Perivascular Organoids to Study Tumor Microenvironment and Drug Sensitivity in Acute Myeloid Leukemia
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III	Abigayle Mazzocco	Assessing Social Media Preferences and Developing Digital Health Care Transition Education Materials for Emerging Adults with Sickle Cell Disease: A Mixed Method Pilot Study
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III	Jason Stevenson, MD	Association of Race, Ethnicity, and Social Deprivation on the Incidence and Severity of Adverse Events in Induction in Children with Acute Lymphoblastic Leukemia
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	907. Outcomes Research: Plasma Cell Disorders: Poster III	Craig Hofmeister, MD	Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III	Shayna Jankowski	The Dominant Effect of the Gut Microbiome on GvHD in Mouse Models of Allo-BMT
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	907. Outcomes Research: Plasma Cell Disorders: Poster III	Craig Hofmeister, MD	Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III	Grace Kalmus, MPH	Lapses in Appointment Attendance Among Children with Sickle Cell Disease in the First Five Years of Life
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III	Melinda G Pauly, MD	Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III	Fanyuan Zeng	VIP Expression Drives an Immunosuppressive Tumor Microenvironment in TP53-Mutated AML
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III	Craig C. Hofmeister, MD	A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	621. Lymphomas: Translational – Molecular and Genetic: Poster III	Michelle J. Lee, MD, PhD	Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients

6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II	Robert F. Sidonio Jr., MD	Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate Among Von Willebrand Disease Patients across All ABO Antigen Blood Groups
-----------------	-----------------------------------------	--------	-------------------------------------------------------------------------------------------------------------------------------------	---------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------